151 related articles for article (PubMed ID: 1821916)
1. [Serum thyroglobulin and whole-body scanning as markers in the follow-up of differentiated thyroid carcinomas].
Degrossi OJ; Rozados IB; Damilano S; Degrossi EB; de Ganino L; Pinkas M; García del Río H; Artagaveytía D
Medicina (B Aires); 1991; 51(4):291-5. PubMed ID: 1821916
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
3. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma?
Ronga G; Fiorentino A; Paserio E; Signore A; Todino V; Tummarello MA; Filesi M; Baschieri I
J Nucl Med; 1990 Nov; 31(11):1766-71. PubMed ID: 2121913
[TBL] [Abstract][Full Text] [Related]
4. [Serum thyroglobulin in the diagnosis of metastases of differentiated thyroid cancer. Effect of suppressive thyroid hormone substitution on the diagnostic accuracy of thyroglobulin values].
Müller-Gärtner HW; Schneider C; Tempel MT
Nuklearmedizin; 1986 Oct; 25(5):194-200. PubMed ID: 3797259
[TBL] [Abstract][Full Text] [Related]
5. [Use of serum thyroglobulin determination in the follow-up of differentiated carcinomas of the thyroid].
Secades Ariz I; Pérez Piqueras JL; Labanda Tejedor P; Cordero Peinado J
An Med Interna; 1988 Sep; 5(9):439-43. PubMed ID: 2856622
[No Abstract] [Full Text] [Related]
6. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
7. Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma.
Ronga G; Fiorentino A; Fragasso G; Fringuelli FM; Todino V
Ital J Surg Sci; 1986; 16(1):11-5. PubMed ID: 3087907
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
Roelants V; Nayer PD; Bouckaert A; Beckers C
Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
[TBL] [Abstract][Full Text] [Related]
9. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
[TBL] [Abstract][Full Text] [Related]
10. [The correlation between serum thyroglobulin and iodine-131 scanning in detecting metastases in patients with a differentiated thyroid carcinoma].
Abduluakhab M; Gavrilov M; Mladenov B
Khirurgiia (Sofiia); 1997; 50(4):33-6. PubMed ID: 9739856
[TBL] [Abstract][Full Text] [Related]
11. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
van Tol KM; Jager PL; de Vries EG; Piers DA; Boezen HM; Sluiter WJ; Dullaart RP; Links TP
Eur J Endocrinol; 2003 Jun; 148(6):589-96. PubMed ID: 12773129
[TBL] [Abstract][Full Text] [Related]
12. Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis.
Huang SH; Wang PW; Huang YE; Chou FF; Liu RT; Tung SC; Chen JF; Kuo MC; Hsieh JR; Hsieh HH
Thyroid; 2006 Dec; 16(12):1273-8. PubMed ID: 17199438
[TBL] [Abstract][Full Text] [Related]
13. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma.
Dadparvar S; Krishna L; Brady LW; Slizofski WJ; Brown SJ; Chevres A; Micaily B
Cancer; 1993 Jun; 71(11):3767-73. PubMed ID: 8490927
[TBL] [Abstract][Full Text] [Related]
14. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
15. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
16. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
[TBL] [Abstract][Full Text] [Related]
17. Thyroglobulin in patients with differentiated thyroid carcinoma.
Lindegaard MW; Paus E
Scand J Clin Lab Invest Suppl; 1991; 206():79-84. PubMed ID: 1947763
[TBL] [Abstract][Full Text] [Related]
18. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
Kim WG; Ryu JS; Kim EY; Lee JH; Baek JH; Yoon JH; Hong SJ; Kim ES; Kim TY; Kim WB; Shong YK
J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases.
Torlontano M; Attard M; Crocetti U; Tumino S; Bruno R; Costante G; D'Azzò G; Meringolo D; Ferretti E; Sacco R; Arturi F; Filetti S
J Clin Endocrinol Metab; 2004 Jul; 89(7):3402-7. PubMed ID: 15240622
[TBL] [Abstract][Full Text] [Related]
20. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
